BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRANSFER WITH VALOCTOCOGENE ROXAPARVOVEC: RESULTS FROM GENER8-1
MC Ozeloa, J Mahlangub, B Madanc, J Masond,e, F Peyvandif,g, AV Drygalskih, G Yamaguti-Hayakawaa, TM Robinsoni, SW Pipej, TT Gener-Eighk
a Department of Internal Medicine, Faculdade de Ciências Médicas (FCM), Centro de Hematologia e Hemoterapia (Hemocentro), Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
b Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and NHLS, Johannesburg, South Africa
c Guy's & St. Thomas'NHS Foundation Trust, London, UK
d University of Queensland, Brisbane, Australia
e Queensland Haemophilia Centre, Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia
f Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
g Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy
h Department of Medicine, University of California San Diego, San Diego, United States
i BioMarin Pharmaceutical, Inc., Novato, United States
j Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, United States
k GENEr8-1 Trial Centers
Ver másRead
295
Timeswas read the article
144
Total PDF
151
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 May | 28 | 23 | 51 |
| 2024 April | 24 | 8 | 32 |
| 2024 March | 23 | 17 | 40 |
| 2024 February | 26 | 22 | 48 |
| 2024 January | 18 | 18 | 36 |
| 2023 December | 19 | 29 | 48 |
| 2023 November | 12 | 21 | 33 |
| 2023 October | 1 | 6 | 7 |
